Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MAP Pharmaceuticals Updates On Levadex Development Program
MAP Pharmaceuticals confirmed with the FDA that four clinical trials, which already were included in the company’s operating budget, are required to support a new drug application (NDA)
MAP Pharmaceuticals confirmed with the FDA that four clinical trials, which already were included in the company’s operating budget, are required to support a new drug application (NDA)
Opexa said that the newly issued patents are US patent nos 7,695,713 and 7,658,926, the granted claims of which are directed to its proprietary process for manufacturing its
Critical Outcome Technologies said that the gap analysis is conducted prior to an initial meeting with the FDA to identify potential deficiencies in the preclinical development program of
EntreMed said that the study is expected to be open at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Massachusetts General Hospital and Beth Israel Deaconess Medical Center, all
The Phase I study is expected to evaluate the localisation, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localised prostate cancer. SL052
Compugen said that in recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, has demonstrated broad expression in human multiple
The goal of the research is to develop blood tests for the early detection or more accurate diagnosis of cancer. Aushon 2470 Arrayer has been installed in institutions
Helsinn Group said that Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 Receptor Antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer,
Soligenix said that the new patent’s main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower
Cipher Pharma is currently preparing for the US commercial launch of Cip-Tramadol, which includes securing a marketing partner and finalising commercial manufacturing requirements. Cipher Pharma said that the